Meta-Analysis of nanoparticulate paclitaxel delivery system pharmacokinetics and model prediction of associated neutropenia

Pharmaceutical Research

Volumn 29, Issue 10, 2012, Pages 2833-2844

  Ait Oudhia, Sihem ^a   Straubinger, Robert M ^a   Mager, Donald E ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Drug delivery; Meta Analysis; Neutropenia; Paclitaxel; Pharmacokinetics

Indexed keywords

ALBUMIN; CREMOPHOR; LEP ETU; LIPOSOME; NANOPARTICLE; PACLITAXEL; TOCOPHEROL; TOCOSOL; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED DRUG RELEASE; DISEASE SEVERITY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; HUMAN; NEUTROPENIA; PRIORITY JOURNAL; SIMULATION; STATISTICAL ANALYSIS;

ALBUMINS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; NANOPARTICLES; NEUTROPENIA; PACLITAXEL; POLYETHYLENE GLYCOLS; TOCOPHEROLS;

EID: 84866735861     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0775-8     Document Type: Article

References (49)

1. ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet. 2003;42:665-85.
2. Rowinskyand EK, Donehower RC. Paclitaxel (taxol). N Engl J Med. 1995;332:1004-14.
3. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, et al. Hypersensitivity reactions from taxol. J Clin Oncol. 1990;8:1263-8.
4. Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H, et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res. 1999;59:1454-7.
5. Brat DJ, Windebank AJ, Brimijoin S. Emulsifier for intravenous cyclosporin inhibits neurite outgrowth, causes deficits in rapid axonal transport and leads to structural abnormalities in differentiating N1E.115 neuroblastoma. J Pharmacol Exp Ther. 1992;261:803-10.
6. Rowinsky EK, Burke PJ, Karp JE, Tucker RW, Ettinger DS, Donehower RC. Phase I and pharmacodynamic study of taxol in refractory acute leukemias. Cancer Res. 1989;49:4640-7.
7. Stinchcombe TE. Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel. Nanomedicine (Lond). 2007;2:415-23.
8. Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res. 2002;8:1038-44.
9. Robinsonand DM, Keating GM. Albumin-bound Paclitaxel: in metastatic breast cancer. Drugs. 2006;66:941-8.
10. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23:7794-803.
11. Desai N, Trieu V, Damascelli B, Soon-Shiong P. SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl Oncol. 2009;2:59-64.
12. Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A, et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res. 2005;11:4136-43.
13. Yamada K, Yamamoto N, Yamada Y, Mukohara T, Minami H, Tamura T. Phase I and pharmacokinetic study of ABI-007, albumin-bound paclitaxel, administered every 3 weeks in Japanese patients with solid tumors. Jpn J Clin Oncol. 2010;40:404-11.
14. Gardner ER, Dahut WL, Scripture CD, Jones J, Aragon-Ching JB, Desai N, et al. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res. 2008;14:4200-5.
15. Zhang JA, Anyarambhatla G, Ma L, Ugwu S, Xuan T, Sardone T, et al. Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation. Eur J Pharm Biopharm. 2005;59:177-87.
16. Fetterly GJ, Grasela TH, Sherman JW, Dul JL, Grahn A, Lecomte D, et al. Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposomeentrapped paclitaxel. Clin Cancer Res. 2008;14:5856-63.
17. Fetterly GJ, Straubinger RM. Pharmacokinetics of paclitaxelcontaining liposomes in rats. AAPS PharmSci. 2003;5:E32.
18. Constantinides PP, Tustian A, Kessler DR. Tocol emulsions for drug solubilization and parenteral delivery. Adv Drug Deliv Rev. 2004;56:1243-55.
19. Constantinides PP, Lambert KJ, Tustian AK, Schneider B, Lalji S, Ma W, et al. Formulation development and antitumor activity of a filter-sterilizable emulsion of paclitaxel. PharmRes. 2000;17:175-82.
20. Perez EA. Novel enhanced delivery taxanes: an update. Semin Oncol. 2007;34(suppl 1-5).
21. Bulitta JB, Zhao P, Arnold RD, Kessler DR, Daifuku R, Pratt J, et al. Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients. Cancer Chemother Pharmacol. 2009;63:1049-63.
22. Bogdanova N, Karaseva N, Ognerubov N, Golubeva O, Weiden P. Paclitaxel injectable emulsion: phase 2a study of weekly administration in patients with non-small lung cancer (NSCLC). J Clin Oncol. (ASCO Annual Meeting Proceedings). 2004;22: abstract No. 7133.
23. Bulitta JB, Zhao P, Arnold RD, Kessler DR, Daifuku R, Pratt J, et al. Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients. Cancer Chemother Pharmacol. 2009;63:1035-48.
24. Gianni L, Kearns CM, Giani A, Capri G, Vigano L, Lacatelli A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol. 1995;13:180-90.
25. Biakhov MY, Kononova GV, Iglesias J, Desai N, Bhar P, Schmid AN, et al. nab-Paclitaxel in patients with advanced solid tumors and hepatic dysfunction: a pilot study. Expert Opin Drug Saf. 2010;9:515-23.
26. Brouwer E, Verweij J, De Bruijn P, Loos WJ, PillayM, Buijs D, et al. Measurement of fraction unbound paclitaxel in human plasma.Drug Metab Dispos. 2000;28:1141-5.
27. Brouwer E, Verweij J, Hauns B, Loos WJ, Nooter K, Mross K, et al. Linearized colorimetric assay for cremophor EL: application to pharmacokinetics after 1-hour paclitaxel infusions. Anal Biochem. 1998;261:198-202.
28. Lim WT, Tan EH, Toh CK, Hee SW, Leong SS, Ang PC, et al. Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol-PM) in patients with solid tumors. Ann Oncol. 2010;21:382-8.
29. Nyman DW, Campbell KJ, Hersh E, Long K, Richardson K, Trieu V, et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol. 2005;23:7785-93.
30. Rischin D, Webster LK, Millward MJ, Linahan BM, Toner GC, Woollett AM, et al. Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel. J Natl Cancer Inst. 1996;88:1297-301.
31. Sparreboom A, Loos WJ, Verweij J, de Vos AI, van der Burg ME, Stoter G, et al. Quantitation of Cremophor EL in human plasma samples using a colorimetric dye-binding microassay. Anal Biochem. 1998;255:171-5.
32. van Tellingen O, Huizing MT, Panday VR, Schellens JH, Nooijen WJ, Beijnen JH. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer. 1999;81:330-5.
33. Gelderblom H, Verweij J, van Zomeren DM, Buijs D, Ouwens L, Nooter K, et al. Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel. Clin Cancer Res. 2002;8:1237-41.
34. Kearns CM, Gianni L, Egorin MJ. Paclitaxel pharmacokinetics and pharmacodynamics. Semin Oncol. 1995;22:16-23.
35. van den Bongard HJ, Mathot RA, van Tellingen O, Schellens JH, Beijnen JH. A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling. Cancer Chemother Pharmacol. 2002;50:16-24.
36. van Zuylen L, Gianni L, Verweij J, Mross K, Brouwer E, Loos WJ, et al. Inter-relationships of paclitaxel disposition, infusion duration and cremophor EL kinetics in cancer patients. Anticancer Drugs. 2000;11:331-7.
37. Lopez-Berestein G, Kasi L, Rosenblum MG, Haynie T, Jahns M, Glenn H, et al. Clinical pharmacology of 99mTc-labeled liposomes in patients with cancer. Cancer Res. 1984;44:375-8.
38. Sparreboom A, van Tellingen O, Huizing MT, Nooijen WJ, Beijnen JH. Determination of polyoxyethyleneglycerol triricinoleate 35 (Cremophor EL) in plasma by pre-column derivatization and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1996;681:355-62.
39. Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001;28:507-32.
40. Oeltmannand T, Frankel A. Advances in immunotoxins. FASEB J. 1991;5:2334-7.
41. Abraxis Bioscience. Nanoparticle albumin bound (nab) technology: A nanotechnology platform for biologically interactive drug delivery and targeting. FDA Briefing Document 06n0107/06n-0107-ts00015-Desai.ppt, FDA Oncologic Drugs Advisory Committee Meeting September 7, 2006. Available from: www.fda.gov/ohrms/dockets/dockets/06n0107/06n-0107-ts00015-Desai.ppt.
42. Henningsson A, Karlsson MO, Vigano L, Gianni L, Verweij J, Sparreboom A. Mechanism-based pharmacokinetic model for paclitaxel. J Clin Oncol. 2001;19:4065-73.
43. Henningsson A, Sparreboom A, Sandstrom M, Freijs A, Larsson R, Bergh J, et al. Population pharmacokineticmodelling of unbound and total plasma concentrations of paclitaxel in cancer patients. Eur J Cancer. 2003;39:1105-14.
44. Huizing MT, Keung AC, Rosing H, van der Kuij V, ten Bokkel Huinink WW, Mandjes IM, et al. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinumpretreated ovarian cancer patients. J Clin Oncol. 1993;11:2127-35.
45. Food and Drug Administration. Introduction or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. Available from: http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/ CriticalPathOpportunitiesReports/ucm077262.htm.
46. Paal K, Muller J, Hegedus L. High affinity binding of paclitaxel to human serum albumin. Eur J Biochem. 2001;268:2187-91.
47. US Food and Drug Administration -Center for Drug Evaluation and Research. FDA Briefing Document 2006-4235S2-02-01-FDAAbraxane.ppt. FDA Oncologic Drugs Advisory Committee Meeting September 7, 2006. Available from: http://www. fda.gov/ohrms/dockets/ac/06/slides/2006-4235S2-02-01-FDAAbraxane.ppt.
48. Nabholtz JM, Gelmon K, Bontenbal M, Spielmann M, Catimel G, Conte P, et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol. 1996;14:1858-67.
49. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol. 2002;20:4713-21.